Biogen, Elan post Tysabri-fueled sales hikes; KKR wins European nod for Capsugel deal;

@FiercePharma: Cal/OSHA fines Baxter for plant safety violations. News | Follow @FiercePharma

> Biogen Idec's second-quarter sales beat analyst expectations, fueled by fast growth in new prescriptions of its multiple sclerosis drug Tysabri. Story

> Private equity firm KKR won European approval for its $2.38 billion deal to buy Pfizer's Capsugel unit. Article

> Elan's Q2 profits grew $59.7 million, beating analyst estimates, on strong sales of Tysabri; the company raised its full-year profits target. Piece

> Gilead Sciences posted a rise in second-quarter profits to $746.2 million, fueled by street-beating sales of its leading HIV products. Article

> Takeda Pharmaceutical said it would borrow ¥600 billion ($7.66 billion) to finance its ¥1.1 trillion buyout of the Swiss drugmaker Nycomed. News

> Hospira posted a 10% hike in second-quarter sales to $1.06 billion, aided in part by strong U.S. revenues from its prostate cancer drug oncolytic docetaxel. Report

> New products helped boost Mylan's generic-drug sales in the U.S., but European sales suffered from pricing pressures. Report

> U.S antitrust regulators approved Perrigo's purchase of Paddock Labs, on the condition that it sell off 6 generic drugs and agree to provisions that would ensure competition in the market for testosterone gel products. Story

> Hexal, a unit of the Novartis generic operation Sandoz, said it withdrew from FDA an application to market its version of the Roche cancer drug Bondronat. More

> Shire said investment banker Susan Kilsby, most recently a senior advisor at Credit Suisse, has joined its board. Report

Biotech News

@FierceBiotech: GSK relying on Ph3 strategy in R&D comeback bid. Piece | Follow @FierceBiotech

@JohnCFierce: Worked with Cetero? FDA cites "corrupt" CRO for widespread falsification News | Follow @JohnCFierce

@RyanMFierce: If you were meeting with Biogen CEO George Scangos today, what would you ask him? Soliciting comments ahead of my trip to $BIIB in Weston. | Follow @RyanMFierce

@MaureenFierce: Ford, Toyota jump into medical device business with ECG-sensing cars. Story | Follow @MaureenFierce

> FDA cites "corrupt" CRO for widespread falsification. Report

> Cancer drug upstart adds $18M in venture cash to state grant. News

> Bayer partners on Trius' Ph3 antibiotic in $94M pact. More

> Amylin heading back to the FDA with Bydureon app. Article

> Survey: Clinical trial costs spike on bigger staffs, recruiting costs. Item

Drug Delivery News

> SPANosomes deliver siRNA more effectively. More

> Zcube, Caltech get together for nanotube-needle drug delivery. Article

> Nanowires are actually swimmers for drug delivery bots. Story

> E-cigarrettes blasted as dangerous drug delivery devices in NEJM. Article

Medical Devices News

> CareFusion to sell ResMed ventilators in U.S. Report

> Medtronic beats Boston Scientific in drug-eluting stent studies. More

> Sunshine Heart raises $5M, readies for C-pulse trials. Article

> IOM report on changes in medical devices approvals expected on Friday. News

> Toyota unveils steering-wheel ECG sensors. Story

> Report: In-home medical devices must be easier to use. Report

And Finally... Is it possible to predict whether someone is likely to survive or die suddenly from a heart attack? Report

Suggested Articles

Merck's Keytruda has new long-term survival results that the drugmaker hopes will help bolster its position in first-line NSCLC.

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.